CA Patent

CA2834602C — Pyruvate kinase activators for use in therapy

Assigned to Agios Pharmaceuticals Inc · Expires 2020-10-06 · 6y expired

What this patent protects

Compounds of formula (l) for use at increasing the lifetime of red blood cells (RBCs) through activating pyruvine kynase mechanism, compositions and use thereof.

USPTO Abstract

Compounds of formula (l) for use at increasing the lifetime of red blood cells (RBCs) through activating pyruvine kynase mechanism, compositions and use thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA2834602C
Jurisdiction
CA
Classification
—
Expires
2020-10-06
Drug substance claim
No
Drug product claim
No
Assignee
Agios Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.